MX2017007044A - Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. - Google Patents

Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.

Info

Publication number
MX2017007044A
MX2017007044A MX2017007044A MX2017007044A MX2017007044A MX 2017007044 A MX2017007044 A MX 2017007044A MX 2017007044 A MX2017007044 A MX 2017007044A MX 2017007044 A MX2017007044 A MX 2017007044A MX 2017007044 A MX2017007044 A MX 2017007044A
Authority
MX
Mexico
Prior art keywords
prophylaxis
treatment
thiazolo
pyrimidine
amino
Prior art date
Application number
MX2017007044A
Other languages
English (en)
Inventor
Feng Song
Gao Lu
Wang Lisha
Yun Hongying
Zheng Xiufang
Wang Baoxia
Li Chao
Chen Dongdong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017007044A publication Critical patent/MX2017007044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), ver fórmula (I), en la que R1, R2 y R3 son como se describen en el presente documento, y a sus profármacos 5 o una sal, enantiómero o diastereómero farmacéuticamente aceptable de los mismos, y a composiciones que incluye los compuestos y a métodos para usar los compuestos.
MX2017007044A 2014-12-08 2015-12-03 Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. MX2017007044A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014093224 2014-12-08
CN2015086987 2015-08-14
PCT/EP2015/078439 WO2016091698A1 (en) 2014-12-08 2015-12-03 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
MX2017007044A true MX2017007044A (es) 2017-11-08

Family

ID=54771116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007044A MX2017007044A (es) 2014-12-08 2015-12-03 Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.

Country Status (31)

Country Link
US (4) US9441008B2 (es)
EP (1) EP3230298B1 (es)
JP (1) JP6817217B2 (es)
KR (2) KR102557560B1 (es)
CN (2) CN107445980B (es)
AU (1) AU2015359692B2 (es)
BR (1) BR112017011941B1 (es)
CA (1) CA2963717C (es)
CL (1) CL2017001426A1 (es)
CR (1) CR20170237A (es)
DK (1) DK3230298T3 (es)
EA (1) EA038744B1 (es)
ES (1) ES2864223T3 (es)
HK (1) HK1245764A1 (es)
HR (1) HRP20210454T1 (es)
HU (1) HUE053704T2 (es)
IL (1) IL251285B (es)
LT (1) LT3230298T (es)
MA (1) MA41134B1 (es)
MX (1) MX2017007044A (es)
MY (1) MY194002A (es)
PE (1) PE20170679A1 (es)
PH (1) PH12017501061B1 (es)
PL (1) PL3230298T3 (es)
PT (1) PT3230298T (es)
RS (1) RS61612B1 (es)
SG (1) SG11201704512PA (es)
SI (1) SI3230298T1 (es)
TW (1) TWI733656B (es)
UA (1) UA124184C2 (es)
WO (1) WO2016091698A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61612B1 (sr) * 2014-12-08 2021-04-29 Hoffmann La Roche 3-supstituisana 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion jedinjenja za lečenje i profilaksu virusne infekcije
KR20170113658A (ko) 2015-03-16 2017-10-12 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
CN107592864B (zh) 2015-05-12 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
BR112019013884A2 (pt) 2017-01-06 2020-03-03 F. Hoffmann-La Roche Ag Processo para a preparação de compostos de 5 -amino -6h´ -tiazolo [4,5 -d] pirimidina -2,7 -diona 3 -substituídos
CN110167947B (zh) * 2017-01-06 2022-05-03 豪夫迈·罗氏有限公司 乙酸[(1S)-1-[(2S,4R,5R)-5-(5-氨基-2-氧代-噻唑并[4,5-d]嘧啶-3-基)-4-羟基-四氢呋喃-2-基]丙基]酯的固体形式
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CA3084667A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
SG11202011667WA (en) * 2018-05-25 2020-12-30 Primmune Therapeutics Inc Tlr7 agonists
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR20210137518A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
CN113543851A (zh) 2019-03-07 2021-10-22 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
JP2023503996A (ja) 2019-11-26 2023-02-01 プリミューン・セラピューティクス・インコーポレイテッド Ｔｌｒ７アゴニスト
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
AU2020415322A1 (en) 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
MX2022007911A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
JP2023536945A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
AU2021322891A1 (en) 2020-08-05 2023-03-09 Dicerna Pharmaceuticals, Inc. Oligonucleotide treatment of hepatitis B patients
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4430184A2 (en) 2021-11-11 2024-09-18 F. Hoffmann-La Roche AG Pharmaceutical combinations for treatment of hbv

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
WO2005016235A2 (en) 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
PT1824482E (pt) * 2004-12-17 2014-05-13 Anadys Pharmaceuticals Inc Compostos 3h-oxazolo e 3h-tiazolo[4,5-d]pirimidin-2-ona 3,5- -di-substituídos e 3,5,7-tri-substituídos e seus pró- -fármacos
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
SG152296A1 (en) 2005-11-21 2009-05-29 Anadys Pharmaceuticals Inc Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CA2655904C (en) * 2006-06-22 2014-11-18 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-.beta.-d-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
JP5225991B2 (ja) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク チアゾロ［４，５−ｄ］ピリミジンのカーボネート及びカルバメートプロドラッグ
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
RS61612B1 (sr) * 2014-12-08 2021-04-29 Hoffmann La Roche 3-supstituisana 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion jedinjenja za lečenje i profilaksu virusne infekcije
KR20170113658A (ko) 2015-03-16 2017-10-12 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
CN107592864B (zh) 2015-05-12 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
WO2016091698A1 (en) 2016-06-16
US20160326209A1 (en) 2016-11-10
ES2864223T3 (es) 2021-10-13
AU2015359692A1 (en) 2017-04-06
UA124184C2 (uk) 2021-08-04
HK1245764A1 (zh) 2018-08-31
NZ730398A (en) 2023-12-22
CA2963717A1 (en) 2016-06-16
CL2017001426A1 (es) 2018-02-16
DK3230298T3 (da) 2021-03-22
IL251285B (en) 2021-10-31
TW201629072A (zh) 2016-08-16
HUE053704T2 (hu) 2021-07-28
MA41134B1 (fr) 2021-03-31
SI3230298T1 (sl) 2021-04-30
BR112017011941B1 (pt) 2023-02-28
CN106164079B (zh) 2017-10-20
PH12017501061A1 (en) 2017-12-11
CN107445980A (zh) 2017-12-08
PE20170679A1 (es) 2017-05-22
CN107445980B (zh) 2021-04-20
EP3230298A1 (en) 2017-10-18
CR20170237A (es) 2017-08-10
JP6817217B2 (ja) 2021-01-20
US9441008B2 (en) 2016-09-13
US10618929B2 (en) 2020-04-14
JP2017537158A (ja) 2017-12-14
KR20230113824A (ko) 2023-08-01
TWI733656B (zh) 2021-07-21
RS61612B1 (sr) 2021-04-29
PT3230298T (pt) 2021-03-15
CA2963717C (en) 2023-10-10
EP3230298B1 (en) 2021-01-20
CN106164079A (zh) 2016-11-23
SG11201704512PA (en) 2017-07-28
US11180525B2 (en) 2021-11-23
US10040815B2 (en) 2018-08-07
KR102557560B1 (ko) 2023-07-20
MY194002A (en) 2022-11-07
IL251285A0 (en) 2017-05-29
US20190169222A1 (en) 2019-06-06
EA201791011A1 (ru) 2017-10-31
US20200239514A1 (en) 2020-07-30
BR112017011941A2 (pt) 2017-12-26
EA038744B1 (ru) 2021-10-13
LT3230298T (lt) 2021-04-12
PL3230298T3 (pl) 2021-06-14
AU2015359692B2 (en) 2020-07-09
US20160194350A1 (en) 2016-07-07
MA41134A (fr) 2017-10-18
KR20170088869A (ko) 2017-08-02
PH12017501061B1 (en) 2017-12-11
HRP20210454T1 (hr) 2021-04-30

Similar Documents

Publication Publication Date Title
PH12017501061A1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12019500432A1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2023001876A (es) Derivados de rapamicina.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MY197698A (en) Oxysterols and methods of use thereof
MX2017001284A (es) Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio.
AU2018253590A1 (en) Imidazopyridazine compounds
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MY191352A (en) Aldosterone synthase inhibitors
EA201491982A1 (ru) Антибактериальные хинолиновые производные
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.